Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03837015
Other study ID # CTN308
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 4, 2019
Est. completion date December 14, 2021

Study information

Verified date December 2021
Source McMaster University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will enrol African, Caribbean and Black (ACB) women who are known to have a more diverse vaginal microbiome, higher rates of bacterial vaginosis with lower numbers of protective lactobacilli, and are at increased risk for HIV. The investigators will evaluate the safety, feasibility, effect on the vaginal bacterial microbiome and changes in local immune and inflammatory responses with the administration of vaginal estrogen alone, vaginal estrogen in combination with oral or vaginally administered probiotics, or vaginal probiotics alone.


Description:

Women are at increased risk of HIV acquisition compared with men. A number of biological factors are associated with increased risk, many of which likely enhance risk by increasing inflammation in the female genital tract. Susceptibility to infections and immune responses in the female genital tract are regulated by hormones: progesterone increases inflammation and HIV susceptibility and estrogen decreases inflammation and enhances colonization with Lactobacilli. A Lactobacillus dominant vaginal microbiome is associated with increased protection against HIV, while a polymicrobial vaginal flora, as seen in bacterial vaginosis, is associated with increased risk. About 40% of ACB women have a polymicrobial flora. The goal of this study is to establish a Lactobacillus dominant vaginal microbiome in ACB women, that will be associated with decreased inflammation and decreased susceptibility to HIV, by administering a low level of intravaginal estrogen to increase colonization with Lactobacilli together with a Lactobacillus-containing probiotic.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 14, 2021
Est. primary completion date December 14, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: - African, Caribbean, Black - Pre-menopausal women in good general health, as determined by the investigator - Uterus and cervix present - Negative pregnancy test - Currently practicing barrier or non-hormonal forms of contraception, and planning to continue, for the duration of the study (barrier contraceptive, abstinence) - Willing to undergo a pelvic exam by a female nurse/female doctor - Willing to abstain from vaginal intercourse for 48 hours prior to sampling, over the entire course of the study - Able to understand, comply and consent to protocol requirements and instructions - Able to attend scheduled study visits and complete required investigations Exclusion Criteria: - Currently lactating - Pregnant: suspected, current or in the last 12 months - Irregular menstrual cycle (less than 6 periods in a year) not related to contraceptive use, pregnancy or breastfeeding - Post-menopausal - Hormonal Contraceptive use or other hormonal treatment in the past 3 months - Current Intra-Uterine Device (IUD) use - Positive test result for Gonorrhea and/or Chlamydia - Clinically obvious genital ulceration/lesions - Symptomatic vaginal yeast infection or clinically significant vaginal discharge - HIV-positive - Any clinically significant abnormality on screening safety blood tests, that in the opinion of the investigator would preclude enrolment. - Diagnosed blood clotting disorder - Any genital tract procedure (e.g. biopsy) within the past 6 months - Use of oral probiotic supplement, oral antibiotics or oral steroids within the past 30 days - Current use of any vaginal products (except tampons) such as spermicides, microbicides, douching or drying products, antifungals, or steroids. - Known intolerance of Lactobacillus-containing probiotic supplements - Undiagnosed abnormal genital bleeding - Known, suspected, or history of breast cancer - Known or suspected estrogen-dependent malignant neoplasia (e.g. endometrial cancer) - Currently taking immunosuppressive drugs - Known or suspected hypersensitivity to any component of the Estring or RepHresh Pro-B products - Diagnosis of endometrial hyperplasia - Known liver dysfunction or disease; as long as liver function tests have failed to return to normal - Active or past history of arterial thromboembolic disease (e.g. stroke, myocardial infarction, coronary heart disease) - Partial or complete loss of vision due to ophthalmic vascular disease - Porphyria - Concomitant medication which in the opinion of the investigator may be associated with a significant drug interaction with the estrogen in Estring. - The conditions below are grounds for exclusion based on the opinion of the investigator: 1. Risk factors for estrogen dependent tumours, e.g. first degree heredity for breast cancer 2. Diabetes mellitus with or without vascular involvement 3. Migraine or (severe) headache 4. Epilepsy 5. A history of, or risk factors for, thromboembolic disorders 6. Systemic lupus erythematosus 7. Otosclerosis 8. Cholelithiasis 9. Leiomyoma (uterine fibroids) 10. Endometriosis 11. A history of endometrial hyperplasia 12. Hypertension 13. Asthma 14. Diagnosed anemia

Study Design


Intervention

Drug:
Estring Vaginal Ring
Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
Other:
RepHresh Pro-B
Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally

Locations

Country Name City State
Canada Women's Health in Women's Hands Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
McMaster University CIHR Canadian HIV Trials Network

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Refusal rate Number of eligible participants approached who do not consent to be enrolled 12 months
Primary Participant retention rate Number of participants who complete the study as proportion of total number of participants enrolled 12 months
Primary Incidence of treatment emergent adverse events The incidence of adverse events, including serious adverse events, their severity and their relationship to study intervention assessed by reviewing case report forms and participant diaries. 2 months
Primary Rate of adherence Adherence will be measured by calculating the total probiotic used/total dispensed and for Estring by total days used/total time period 30 days
Secondary Changes in proportion of Lactobacillus species in the vaginal microbiota Aliquots of cervico-vaginal lavage (CVL) fluids will undergo microbiome analysis using a modified Illumina sequencing method for bacterial community profiling of 16S rRNA to measure changes from baseline at follow-up sampling. 30 days
Secondary Change in innate inflammatory cytokine/chemokine levels Changes from baseline in levels of cytokine/chemokines will be measured in CVL by a 22-plex multiplex assay at 2 and 4 weeks 30 days
Secondary Changes in number of HIV target cells in the genital tract Changes from baseline in level of HIV susceptible CD4+ T cells will be quantified using a lab developed HIV pseudovirus assay at 2 and 4 weeks. 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT03940521 - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Completed NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Completed NCT03570918 - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy Phase 1
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Active, not recruiting NCT04022967 - ANRS 12372 MODERATO Study Phase 3
Not yet recruiting NCT06282783 - Studying Topiramate for Re-Activating the HIV-1 Reservoir Phase 1/Phase 2
Not yet recruiting NCT06337032 - A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments Phase 4
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting NCT03536234 - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients Phase 2
Completed NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4
Withdrawn NCT05769569 - Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission Phase 1
Enrolling by invitation NCT05584397 - Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
Completed NCT04388904 - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) Phase 4
Not yet recruiting NCT04894357 - Impact of V106I on Resistance to Doravirine
Completed NCT04963712 - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Early Phase 1
Not yet recruiting NCT04311957 - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults Phase 4
Not yet recruiting NCT04513496 - Telemedicine in HIV Care in Buenos Aires
Not yet recruiting NCT04311944 - Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD N/A
Completed NCT04568239 - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Completed NCT03998176 - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE Phase 4